Skip to main content
Premium Trial:

Request an Annual Quote

Sprout Group VCs Hire GlaxoSmithKline Exec; Galapagos Adds CSO

NEW YORK, May 29 - Venture-capital firm Sprout Group has hired former GlaxoSmithKline chief science and technology officer James Niedel, the company said yesterday.

 

Niedel will be venture partner for health-care technology investments.

 

Between 1995 and 2001, Niedel was a board member at Glaxo Wellcome, where he oversaw global R&D, information technology, and product strategy.

 

The Sprout Group is a venture capital affiliate of Credit Suisse First Boston.

 


 

Functional-genomics company Galapagos Genomics said on May 21 that it had hired Robin Brown as chief scientific officer.

 

Brown will direct the company's R&D, particularly in drug target discovery and validation.

 

He was previously chief scientific officer at the Belgian firm Devgen, and prior to that was at Glaxo Wellcome.

 

Galapagos is headquartered in Mechelen, Belgium. It is privately held.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.